Urban et al¹ recently developed the Academic Research Consortium for high bleeding risk (ARC-HBR) trade-off model. The new scores provide the predicted 1-year risk of nonperiprocedural major bleeding (Bleeding Academic Research Consortium [BARC] types 3-5 bleeding) and thrombotic events (myocardial infarction [MI] and/or definite or probable stent thrombosis [ST]) after coronary stenting in patients with HBR. In the development and validation cohorts, the C statistics were 0.68 and 0.74 for major bleeding and 0.68 and 0.74 for thrombotic events, respectively; C statistics in validation cohorts typically are lower than those observed in the development cohort. To support individual optimal antiplatelet therapy, bleeding and thrombotic risk scores should achieve helpful discrimination (C statistics, ≥0.60) in contemporary treatment strategies.² We applied the scores to the GLOBAL LEADERS trial population.³

城市等人¹最近开发了高出血风险（ARC-HBR）权衡模型的学术研究联盟。新评分提供非围手术期大出血（出血学术研究联盟 [BARC] 3-5 型出血）和血栓事件（心肌梗塞 [MI] 和/或确定或可能的支架血栓形成 [ST]）的预测 1 年风险HBR 患者的冠状动脉支架置入术。在开发和验证队列中，大出血的 C 统计量分别为 0.68 和 0.74，血栓事件的 C 统计量分别为 0.68 和 0.74；验证队列中的 C 统计数据通常低于开发队列中观察到的数据。为了支持个体最佳的抗血小板治疗，出血和血栓形成风险评分应在当代治疗策略中实现有益的区分（C统计，≥0.60）。²我们将分数应用于 GLOBAL LEADERS 试验人群。³